Project Grant R41AR079360
Award Date
9/5/21
Completion Date
8/31/22
Dollars Obligated
$756K
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $549,437 Project Grant (R01AR082810) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Trustees of the University of Pennsylvania. The grant's objective is to locally deliver a small molecule Hedgehog signaling agonist to increase the formation of zonal tendon-to-bone attachments and improve outcomes following anterior cruciate ligament (ACL) reconstruction....
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to define the efficacy of pharmacologically activating the G-protein coupled receptor GPR68 to modulate the dynamics of tenocyte-myofibroblast interactions during fibrotic tendon healing. The $203,280 award, running from August 2024 to May 2026, will support research at the University of...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a pro-regenerative engineered extracellular matrix (EECM) scaffold to promote the alignment and regeneration of tendon tissue. The $360,580 award, effective from September 1, 2024, to August 31, 2026, will fund the University of Oregon's research to fabricate anisotropic...
This $766,269 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of ALTENEX, an exosome-based biologic drug derived from human bone marrow mesenchymal stem cells, as a potential treatment for age-related tendinopathy. The funding will enable preclinical studies to evaluate the efficacy, safety, and pharmacokinetics of ALTENEX in animal models, a critical step towards advancing this novel therapeutic intervention for tendon disorders...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $501,450 to The Washington University to conduct research on regulating tendon repair using stem cell-derived extracellular vesicles. The study aims to identify the specific subpopulation and active cargo molecules of extracellular vesicles that can enhance tendon healing and avoid...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $359,133 project grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to generate new genetic tools for advancing tendon and musculoskeletal research. The project aims to develop constitutive and inducible FLP alleles and FLP/CRE dual recombinase responsive alleles to enable more precise...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $621,703 to Cornell University for a 5-year research project. The goal is to investigate the mechanisms by which an increase in glycosaminoglycans, specifically hyaluronan and dermatan sulfate, can modulate the mechanical environment of cells in damaged tendons and promote a reparative...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $525,259.51 to the University of Rochester to conduct research on the role of epitenon-derived progenitor cells in tendon healing and adaptation. The overarching goal is to gain a comprehensive understanding of how epitenon cells and tenocytes coordinate to regulate the tendon's adaptive...
Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded Collamedix Inc. a $300,000 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to establish the feasibility of their "CollaLink" collagen-based scaffold for augmenting primary repair of anterior cruciate ligament (ACL) mid-substance tears. The project aims to demonstrate that the CollaLink scaffold, when placed around an ACL tear, can provide a...